You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
《復牌表現》中國醫療(08225.HK)申請恢復生產對新型冠狀病毒有療效利托那韋 股價續飆1倍
阿思達克 01-30 11:56

中國醫療集團(08225.HK)向藥監局申請恢復生產對新型冠狀病毒(2019-nCoV)有抑制作用和療效的利托那韋(Ritonavir),該股繼昨天飆升2.8倍中途停牌後,今天復牌再續升勢,最多續漲1.2倍至0.95元,接近2015年5月所創上市高位1.01元遇阻,現造0.87元,續漲1倍,成交續增至2.37億股,為數年來罕見,涉資1.65億元。

中國醫療公布,旗下新型冠狀病毒肺炎臨床特別專案組研究發現利托那韋(Ritonavir)對新型冠狀病毒(2019-nCoV)有抑制作用和療效報告,中國科學院武漢病毒研究所等也發現其在細胞層面上對新型冠狀病毒(2019-nCoV)有較好抑制作用。目前集團關聯公司萬全萬特廈門是一家唯一國內歷史生產過該產品製劑,企業同時擁有原料批文,申請相關專利和已經向國家藥監局申請重新恢復生產,集團將負責進一步臨床研究和申報工作。除此之外,公司董事局確認不悉任何導致昨天股價及成交量異常變動之因。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account